ライフサイエンスコーパス: developing country

1 peer support improved uptake (two studies in developing countries).

2 od deficit countries, and net food-importing developing countries).

3 te and agricultural income to self-harm in a developing country.

4 th in patients with suspected infection in a developing country.

5 ly for local laboratories or laboratories in developing countries.

6 ns a major problem in both the developed and developing countries.

7 are globally widespread and are prevalent in developing countries.

8 imary cooks and tend not to smoke tobacco in developing countries.

9 acute gastroenteritis in both developed and developing countries.

10 one of the main causes of mortality in many developing countries.

11 ar up to 200,000 child deaths, mainly in the developing countries.

12 s an increasing cause of infant mortality in developing countries.

13 empts to tackle climate change mitigation in developing countries.

14 dults is substantial, with limited data from developing countries.

15 extensively studied, especially in tropical, developing countries.

16 ed in national immunization programs in many developing countries.

17 cine to control canine-transmitted rabies in developing countries.

18 ving accessibility to medical diagnostics in developing countries.

19 main sources of calories and protein in many developing countries.

20 and the substantial increase in incidence in developing countries.

21 l for fighting vitamin A deficiency (VAD) in developing countries.

22 can expand influenza vaccination coverage in developing countries.

23 ess to drinking water for millions living in developing countries.

24 on RSV has yielded substantial new data from developing countries.

25 ding the design of similar agri-platforms in developing countries.

26 s limiting their applicability especially in developing countries.

27 stating maternal complication of delivery in developing countries.

28 defect recurrence; and studies conducted in developing countries.

29 ion annual deaths worldwide, most of them in developing countries.

30 pares with many reports in the developed and developing countries.

31 nd clinical laboratories, including those in developing countries.

32 well as POC diagnostics in resource-poor and developing countries.

33 e leading causes of blindness, especially in developing countries.

34 en of vision-impairing secondary membrane in developing countries.

35 tis has not been established in developed or developing countries.

36 hus simple tests increase the feasibility in developing countries.

37 marine biodiversity, especially in tropical developing countries.

38 unsafe, with 24.3 million (97%) of these in developing countries.

39 e intestinal disease and infant mortality in developing countries.

40 Cancer is also a growing problem in developing countries.

41 ernative for cancer diagnosis, especially in developing countries.

42 settings, and virtually all deaths occur in developing countries.

43 ssibility and quality of cataract surgery in developing countries.

44 dy diarrhea each year, mostly in children in developing countries.

45 ially contribute to the food security in the developing countries.

46 -class drug still widely used, especially in developing countries.

47 an immunodeficiency virus/AIDS patients from developing countries.

48 temperature-YLL relationship, especially in developing countries.

49 equently overwhelm health care facilities in developing countries.

50 and poses a threat to food-security in many developing countries.

51 been highly successful in both developed and developing countries.

52 he diminished RVV immunogenicity observed in developing countries.

53 ciency, which impedes their extensive use in developing countries.

54 f these tubers is vital for food security in developing countries.

55 ted to cause over 200,000 deaths annually in developing countries.

56 tion (EED) that severely affects children in developing countries.

57 a seroprevalence reaching up to 100% in some developing countries.

58 o control vector-borne diseases continues in developing countries.

59 environmental consequences, particularly in developing countries.

60 long-term growth impairment in children from developing countries.

61 million refugees, mostly in refugee camps in developing countries.

62 main sources of calories and proteins in the developing countries.

63 ies within entrepreneurial ecosystems in six developing countries.

64 challenges to more effective vaccination in developing countries.

65 hain, or cold chain, is rapidly expanding in developing countries.

66 rointestinal illness among young children in developing countries.

67 birth cohort due to growth faltering in 137 developing countries.

68 partners, including vaccine manufacturers in developing countries.

69 ital resource in addressing food security in developing countries.

70 ical service as a public health commodity in developing countries.

71 ied the economic cost of growth faltering in developing countries.

72 e elderly or for patients with endemic BL in developing countries.

73 by the lack of accurate data, especially in developing countries.

74 ral rotavirus vaccines are less effective in developing countries.

75 d world, it presents a significant burden in developing countries.

76 ociated with high mortality, particularly in developing countries.

77 lic health priority worldwide, especially in developing countries.

78 are the leading risk factors for stunting in developing countries.

79 hat can enable more effective vaccination in developing countries.

80 n developed countries, but are increasing in developing countries.

81 sform efforts to track and target poverty in developing countries.

82 s from 24 countries, of which 21 represented developing countries.

83 t are attributable to 18 risk factors in 137 developing countries.

84 d disease surveillance in both developed and developing countries.

85 eprosy in more unfortunate people of certain developing countries.

86 iagnosis of DENV in clinics and hospitals in developing countries.

87 se, but this has been little investigated in developing countries.

88 approximately 3% of individuals traveling to developing countries.

89 der the age of 5 years in both developed and developing countries.

90 l but preventable cause of mortality in many developing countries.

91 hildren under the age of 2 years who live in developing countries.

92 cer health disparities between developed and developing countries.

93 thods used for electronic waste treatment in developing countries.

94 an underrecognized cause of illness in many developing countries.

95 se affecting a large number of people in the developing countries.

96 tries and the emerging cause of blindness in developing countries.

97 ks, and clinical trials of co-trimoxazole in developing countries.

98 tion but the disease is still a challenge in developing countries.

99 portance of implementing such initiatives in developing countries.

100 a major cause of morbidity and mortality in developing countries.

101 lead to an increase in cropland expansion in developing countries.

102 demic proportions in both industrialized and developing countries.

103 auses significant mortality and morbidity in developing countries.

104 s prevalent in the small-farm sector of many developing countries.

105 lic health problem for humans, especially in developing countries.

106 tes remaining fossil fuel production towards developing countries.

107 ean for mosquito control and surveillance in developing countries.

108 and is increasingly provided in emerging and developing countries.

109 vere diarrhea and death in young children in developing countries.

110 bovine tuberculosis is scarce, especially in developing countries.

111 ing cause of mortality and morbidity in many developing countries.

112 eing the most frequently isolated species in developing countries.

113 The situation is less documented in developing countries.

114 be applied in low-resource contexts, such as developing countries.

115 ct patients will expand its applicability in developing countries.

116 working with tropical diseases localized in developing countries.

117 on adjuvants on a large scale, especially in developing countries.

118 l for the diagnosis of infectious disease in developing countries.

119 disability, with an increasing incidence in developing countries.

120 al method for estimating vaccine coverage in developing countries.

121 ource of exposure to indoor air pollution in developing countries.

122 reduce premature mortality and morbidity in developing countries.

123 nfection occurs often in endemic settings in developing countries.

124 al resistance is starting to show up in some developing countries.

125 n below the age of five years, especially in developing countries(1,2).

126 4400 per year), Europe ($4000 per year), and developing countries ($2100 per year).

127 In many developing countries a considerable proportion of CKD re

128 139 are responsible for cholera outbreaks in developing countries accounting for 3-5 million infectio

129 omas (HCCs) is dominated by its incidence in developing countries, accounting for >700,000 estimated

130 ance: Surgical care is widely unavailable in developing countries; advocates recommend that countries

131 ich become especially problematic in certain developing countries along tropical latitudes.

132 mprehensive evaluation of surgical need in a developing country among the elderly.

133 billion (95% CI, 3.47-7.93), 65% of these in developing countries and 55% of global costs accounted f

134 with a ICER of $8.7/QALY, and affordable in developing countries and area where laboratory facilitie

135 invasive amebiasis, which is endemic to many developing countries and characterized by dysentery and

136 review summarizes vaccination challenges in developing countries and discusses advantages that micro

137 whether outcomes are similar for donors from developing countries and donors with pre-existing condit

138 ataract is the leading cause of blindness in developing countries and identification of the barriers

139 gricultural nitrous oxide (N2O) emissions in developing countries and in particular from tropical reg

140 ommonly cause diarrhea in children living in developing countries and in travelers to those regions.

141 cy (A(-)) remains a public health concern in developing countries and is associated with increased su

142 nt was especially magnified among landlocked developing countries and low-income food deficit countri

143 ake of these interventions have been slow in developing countries and many children suffering from di

144 There were few data from developing countries and marked heterogeneity in study d

145 g the changing impacts of the food system in developing countries and may inform future sustainabilit

146 curtailed by increasing hypertension in some developing countries and more importantly global growth

147 e diagnosis of such infections is limited in developing countries and requires modern equipment in ad

148 om studies of residents in or expatriates of developing countries and travelers to these regions wher

149 Rosenkranz Prize for Healthcare Research in Developing Countries and US National Institutes of Healt

150 on status in the United States compared with developing countries and, in turn, included a focus on i

151 fects one-third of children under 5 y old in developing countries, and 14% of childhood deaths are at

152 cessible records are sparse, especially from developing countries, and are frequently inaccurate thro

153 is a significant burden on public health in developing countries, and currently available drugs exhi

154 e to severe diarrhea among young children in developing countries, and EPEC isolates can be subdivide

155 aediatric asthma cases in both developed and developing countries, and especially in urban areas.

156 rtality is high in children aged <5 years in developing countries, and evaluations indicate waning pr

157 xpanded Access to Cancer Care and Control in Developing Countries, and the Union for International Ca

158 However, in developing countries antibiotic therapy is commonly init

159 Developing countries are increasingly decentralizing for

160 ct infection (LRTI) in premature children in developing countries are necessary to elaborate evidence

161 Many developing countries are providing poor fishing househol

162 Developing countries are struggling to meet Aichi Target

163 Studies in developing countries are underrepresented.

164 ffered; India showed similarities with other developing countries (around 50% of DALYs attributable t

165 , it continues to be used in China and other developing countries as a global pollutant.

166 ng virus causing epidemic acute hepatitis in developing countries as well as sporadic cases in indust

167 neumonia in children younger than 5 years in developing countries at 5-year intervals during the Mill

168 uction structure and efficiency gains, while developing countries became the major destination of Chi

169 emain one of the leading causes of deaths in developing countries because of a lack of basic sanitati

170 rculosis is a major cause of pericarditis in developing countries but accounts for less than 5% of ca

171 chistosomiasis is a prevalent disease in the developing countries, but in non-endemic areas diagnosis

172 llution is a severe environmental problem in developing countries, but its challenges to public healt

173 romising low-cost interventions for women in developing countries, but no evidence exists to support

174 common health-care-associated infections in developing countries, but they also represent a substant

175 rs may poorly estimate emissions in tropical developing countries by comparing calculator predictions

176 millions of self-employed business owners in developing countries by teaching basic financial and mar

177 Centralization of care at a single center in developing countries can achieve patient outcomes compar

178 Globally, growth faltering in developing countries caused a total economic cost of $17

179 suggest that early-life growth faltering in developing countries caused a total loss of 69.4 million

180 In rural India, as in many developing countries, childhood mortality remains high a

181 e compared coastal restoration projects in a developing country, China, and a developed country, the

182 European and Developing Countries Clinical Trial Partnership, Medicin

183 The study was funded by the European and Developing Countries Clinical Trials partnership (EDCTP)

184 ire Ontwikkelings Samenwerking, European and Developing Countries Clinical Trials Partnership, and th

185 European Union European and Developing Countries Clinical Trials Partnership.

186 ntimalarial Resistance Network, European and Developing Countries Clinical Trials Partnership.

187 European Developing Countries Clinical Trials Partnership.

188 erved nutrient supply deficits in landlocked developing countries constituted a large percentage (ran

189 In a developing-country context, the International Monetary F

190 As established and developing countries continue to rapidly increase ethano

191 could join the global fleet by midcentury as developing countries continue to transition away from su

192 hat a large proportion of neonatal sepsis in developing countries could be effectively prevented usin

193 C-Kpn within a challenged health system of a developing country created the "perfect storm" for susta

194 However, thousands of people in developing countries die of rabies each year due to the

195 The estimates suggest that overall, in developing countries, dry anomalies account for ~9% of t

196 d more than 2 million people die annually in developing countries due to such pathologies.

197 5) and poor cognitive function is lacking in developing countries, especially in highly polluted area

198 ost 60% of individuals with dementia live in developing countries, few clinicopathological studies fo

199 organizations provide billions of dollars to developing countries for health.

200 in which rich countries provide payments to developing countries for protecting their forests.

201 the global, regional, and national level for developing countries for the Millennium Development Goal

202 ly differentiate the under-studied cities of developing countries from those of western nations, thus

203 ion, and offers limited economic benefit for developing countries given the long timeframe required t

204 cer, a major cause of monocular blindness in developing countries has consistently been listed as the

205 Funding for health in developing countries has increased substantially since 1

206 Trauma care capacity assessments in developing countries have generated evidence to support

207 n are indisputable, studies in developed and developing countries have reported conflicting findings

208 Many developing countries have struggled to control FRD, desp

209 lera and is the leading cause of diarrhea in developing countries, highlighting the need for the deve

210 n supplying food and nutritional security in developing countries in Asia, Africa and the tropical Am

211 s for improving maternal mortality ratios in developing countries in the Sustainable Development Goal

212 estimates of seasonal influenza mortality in developing countries in the tropics are lacking.

213 However, developing countries, in particular, Sub-Saharan African

214 In developing countries, inadequate screening options lead

215 Eye infection is a public health problem in developing countries including Ethiopia.

216 9 y) is becoming increasingly common in many developing countries, including Bangladesh.

217 (PFOS) is an environmental toxicant used in developing countries, including China, as a stain repell

218 susceptibility information are long in many developing countries, including Panama, leading to delay

219 In many developing countries, increased use of fertilizers is a

220 Poor development in young children in developing countries is a major problem.

221 tion of dietary habits in both developed and developing countries is accompanied by a progressive red

222 However, vaccine administration in developing countries is limited by the difficulty in con

223 is an emerging virus found predominately in developing countries; it causes an estimated 20 million

224 early screening of infections especially in developing countries lacking in basic infrastructure and

225 ted globally and by subgroup (EU, landlocked developing countries, least developed countries, low-inc

226 e simplest, cheapest and only method used in developing countries like Ethiopia.

227 y a higher occurrence of reinfection TB in a developing country like Brazil.

228 People in undeveloped and developing countries, like Iran, are more vulnerable and

229 of primary emissions from cookstoves used in developing countries may make important contributions to

230 To reach this target, developing countries must set up large offshore Marine p

231 izations (n = 38) that provided resources to developing countries (n = 146-183, depending on the year

232 However, in developing countries, obfuscation through value-added ta

233 For developing countries, oversight is less intensive, and c

234 man rotavirus genotypes in young children in developing countries play an important role in epidemiol

235 ance of rotavirus and oral polio vaccines in developing countries (PROVIDE) study.

236 me increasingly common in both developed and developing countries, raising legitimate concerns regard

237 specific beneficial effects in children from developing countries, reducing morbidity and mortality c

238 resuscitation protocol on sepsis outcomes in developing countries remains unknown.

239 warming below 2 degrees C while recognizing developing countries' right to eradicate extreme poverty

240 nt pricing scenarios in the USA, Europe, and developing countries, second-generation TKIs at current

241 owever, this is done in several studies from developing country settings in which birthweight is eith

242 ques are particularly challenging for use in developing country settings, where vitamin A deficiency

243 Although developing countries show an increasing trend in the num

244 In the 9 developing country sites, nasopharyngeal/oropharyngeal s

245 In developed and developing countries, social, economic, and environmenta

246 utions on flood exposure calculations for 18 developing countries spread across Africa, Asia and Lati

247 boratories at all tiers of health systems in developing countries, strengthening specimen referral ne

248 In developing countries, such as India, where combustion so

249 le macrosectors, especially when measured on developing countries, suggesting the emerging economies

250 unsafe abortions was significantly higher in developing countries than developed countries (49.5% vs

251 n rates were more than three times higher in developing countries than in industrialized countries (1

252 large patient populations especially in the developing countries that lack sufficient facilities and

253 tiveness of routine rotavirus vaccination in developing countries that were among the early adopters

254 In developing countries, the deployment of medical diagnost

255 Economic water scarcity is severe in the developing countries; thus, the use of inexpensive waste

256 rge multicity studies have been conducted in developing countries to address the acute health effects

257 nce interventions raised completion rates in developing countries to close the global achievement gap

258 rograms operate in poor rural communities in developing countries to establish groups that save and t

259 901 point prevalence surveys of pathogens in developing countries to map resistance in animals.

260 milk alternatives predominantly exported to developing countries to satisfy growing demands for dair

261 h as riverbank filtration (RBF), are used in developing countries to treat irrigation water from rive

262 Increased efforts are needed, especially in developing countries, to ensure access to safe abortion.

263 The huge burden of malaria in developing countries urgently demands the development of

264 We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and

265 pneumonia burden attributable to HIV for 132 developing countries using a risk-factor-based model tha

266 of orally administered rotavirus vaccines in developing countries, vaccine implementation in these se

267 al efficacy of TCV in endemic populations in developing countries, we should remain vigilant and expl

268 ate change entered the political agenda in a developing country, we examine from an agenda-setting pe

269 urveillance studies of infant pertussis in a developing country, we identified a moderate burden of p

270 adults in industrialized countries (data for developing countries were missing), and of these, approx

271 able for elderly patients or for patients in developing countries where BL is endemic.

272 ay have a particularly marked impact in many developing countries where CMV seroprevalence is almost

273 obally, and in particular to remote areas of developing countries where disease rates are often highe

274 sorders have been conducted in (sub)tropical developing countries where exposure to multiple parasite

275 w-income consumers for dairy proteins in the developing countries where food control systems may be f

276 the o2 mutant benefits millions of people in developing countries where maize is a primary protein so

277 o be a major public health problem affecting developing countries where people eat mostly rice as a s

278 health containment efforts, particularly in developing countries where resources are few and EVD is

279 itude of yield gaps is particularly large in developing countries where smallholder farming dominates

280 the demand of effective screening actions in developing countries where the disease is most endemic.

281 us (HEV) is a major public health concern in developing countries where the primary transmission is v

282 c viruses and may have potential benefits in developing countries where the viral cancer burden is hi

283 s are a low-cost alternative, easily used in developing countries where there is a dearth of advanced

284 olium (the pork tapeworm) is present in most developing countries, where it is a frequent cause of se

285 than half of new cases occur in economically developing countries, where more than two thirds of canc

286 xpensive, alternative diagnostic strategy in developing countries, where plaque reduction neutralizat

287 About 80% of affected patients live in developing countries, where pulmonary hypertension is fr

288 ly that such protocols will be applicable in developing countries, where the greatest demand for a be

289 d health benefits result from diet shifts in developing countries whereas Western high-income and mid

290 at an alarming rate worldwide, especially in developing countries which lack the medical infrastructu

291 That these effects are confined to developing countries, which are often dominated by small

292 of infectious diseases each year, mostly in developing countries, which could largely be prevented b

293 ncrease in overweight among individuals from developing countries who have been undernourished as chi

294 ction of rotavirus vaccines, particularly in developing countries with diverse strains and lower effi

295 interrelate with the natural environment in developing countries with high economic disparities.

296 such as guiding safe iron supplementation in developing countries with high infection burden.

297 romising approaches for disease screening in developing countries with limited resources.

298 fever remains a major cause of morbidity in developing countries with poor sanitation conditions tha

299 ee quarters of the world's suicides occur in developing countries, yet little is known about the driv

300 g cause of acute liver failure (ALF) in many developing countries, yet rarely identified in Western c